TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6469553
Drug: Clorurated aminoacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorurated aminoacid solution (10% solution, 1 liter daily)
Study: 6469553
Drug: Acetated aminoacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated aminoacid solution (10% solution, 1 liter daily)
Study: 31448837
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AM (375 mg amoxicillin and 250 mg metronidazole, 8/8 hours, 7 days)
Study: 27505191
Drug: Educational video
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational video about generic medicines
Study: 27505191
Drug: Generic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Generic ibuprofen
Study: 22591195
Drug: CK‐2017357 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK‐2017357 at 250 mg
Study: 22591195
Drug: CK‐2017357 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK‐2017357 at 500 mg
Study: 20177164
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO therapy)
Study: 15290118
Drug: Tetrahydrobiopterin (BH4)
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tetrahydrobiopterin (BH4) 10 mg kg(‐1) body weight over 30 min
Study: 10202392
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g mixed tea oral administration and topical treatment
Study: 10202392
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and glycerin treatment
Study: 8748361
Drug: Glutamine-supplemented enteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented enteral nutrition (0.35 g of glutamine/kg body weight per day)
Study: 8748361
Drug: Isonitrogenous formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonitrogenous formula (0.05 g of glutamine/kg body weight per day)
Study: 2220176
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (NEA) therapy, 50 mg/day for 6 months followed by a 6-month pause, continued for up to 5 years post-op.
Study: 2220176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NEA therapy) after surgery.
Study: 2220176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NEA therapy) after irradiation.
Study: 2220176
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (NEA) therapy.
Study: 730416
Drug: Hydrochlorothiazide +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide + Amiloride (50 + 5 mg)
Study: 30626425
Drug: Stratification based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratification based on levels of CAFs at diagnosis and their variations after therapy
Study: 29980224
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in daily GH dose (IGF‐1 target level of -2 to -1 SDS)
Study: 29980224
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in daily GH dose (IGF‐1 target level of 1 to 2 SDS)
Study: 29980224
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in IGF‐1 levels in females within the low treatment arm
Study: 27713968
Drug: Whole natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole natural almonds (42 g per day)
Study: 27713968
Drug: Whole roasted
Normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole roasted almonds (42 g per day)
Study: 27713968
Drug: Chopped almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chopped almonds (42 g per day)
Study: 27713968
Drug: Almond butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond butter (42 g per day)
Study: 27713968
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g per day)
Study: 10517189
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg/day and doxycycline 200 mg/day for 45 days (group 1)
Study: 10517189
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg/day and ciprofloxacin 1 g/day for 30 days (group 2)
Study: 30944968
Drug: Oral dissolution
Normalized name: Witch Hazel 30 mg in 30 mL TOPICAL PATCH [LEADERS INSOLUTION COCONUT LIFTING RECOVERY MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dissolution therapy (ODT)
Study: 30944968
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (ODT + SWL)
Study: 30536479
Drug: cis100+RT (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis100+RT (high-dose cisplatin 100 mg/m2 on days 1, 22, and 43)
Study: 30536479
Drug: cis40+ART (intermediate-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis40+ART (intermediate-dose cisplatin weekly 40 mg/m2)
Study: 25824211
Drug: Oritavancin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 1,200 mg single dose
Study: 21851906
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg three times daily for 14 days
Study: 19724269
Drug: Routine weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine weekly GMA (one session per week)
Study: 8922243
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and limited field irradiation
Study: 6354209
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tolbutamide injected i.v. every four hours
Study: 31068943
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of miR-181a-5p and miR-155-5p expression post-transplantation
Study: 18580589
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng powder (4.5 g/d) for 12 weeks
Study: 18580589
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ginseng treatment)
Study: 6837492
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar vitamin and mineral supplements without added zinc)
Study: 30952500
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal conjugate vaccine (MCV)
Study: 22188747
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin (200 μl, 5%)
Study: 20171421
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of clopidogrel 75-mg tablets
Study: 20171421
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of clopidogrel 75-mg tablets
Study: 17763408
Drug: Continuous-sequential estrogen-progestogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-sequential estrogen-progestogen regimen (n = 52)
Study: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SonoVue (Bracco) 0.3 ml
Study: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SonoVue (Bracco) 0.6 ml
Study: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SonoVue (Bracco) 1.2 ml
Study: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SonoVue (Bracco) 2.4 ml
Study: 31818310
Drug: Psychosomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic therapy in addition to usual care
Study: 27066903
Drug: Conventional stented
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional stented biological prosthesis (Soprano LivaNova)
Study: 25246162
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly subjects
Study: 25246162
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly males
Study: 25246162
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly females
Study: 25246162
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in non-elderly subjects
Study: 25246162
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate tablet (ZST) 1.75 mg and 3.5 mg in elderly subjects
Study: 25246162
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate tablet (ZST)
Study: 19641358
Drug: Alfuzosin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin XL 10 mg once daily for 2 days
Study: 17726350
Drug: Operative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative and pharmaceutical approaches for treatment of infection stones
Study: 17726350
Drug: Metaphylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaphylactic treatment
Study: 12755527
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of recombinant Hepatitis B vaccine
Study: 12755527
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of recombinant Hepatitis B vaccine
Study: 10338107
Drug: Piracetam 4.8g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 4.8g daily for 12 weeks
Study: 10338107
Drug: Piracetam 12g
DrugBank: Piracetam (DB09210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 12g intravenous bolus, 12g daily for 4 weeks, and 4.8g daily for a further 8 weeks
Study: 10338107
Drug: Piracetam treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam treatment within 7 hours of stroke onset
Study: 1928712
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no rHuEPO treatment)
Study: 30213052
Drug: Half-A (68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-A (68 g fresh Hass avocado)
Study: 30213052
Drug: Whole-A (136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-A (136 g fresh Hass avocado)
Study: 30213052
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g avocado)
Study: 22323869
Drug: Oral solubilized
Normalized name: VITAMIN A PALMITATE (SOLUBILIZED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solubilized UDCA (3.5 g/140 mL/day)
Study: 15857210
Drug: Ganopoly (polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganopoly (polysaccharide extract of G. lucidum)
Study: 30114980
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy model in occupational rehabilitation programme
Study: 24781718
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-adhesion treatment)
Study: 23097096
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg) administered intravenously in three doses, eight hours apart
Study: 3415889
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 20 ml h‐1 (in saline)
Study: 42224
Drug: mepindolol-sulfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepindolol-sulfate (2 x 2.5 mg)
Study: 31787433
Drug: Heparin-coated (HC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated (HC) circuits
Study: 31445354
Drug: Necitumumab (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necitumumab (800 mg) with nab-paclitaxel (100 mg/m2) and carboplatin (AUC 6 mg*min/mL) for 4 cycles, followed by necitumumab and nab-paclitaxel maintenance
Study: 29234057
Drug: Carnosine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine supplementation (2g daily for 12 weeks)
Study: 23401618
Drug: E2 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 administration during the last 7 days of GnRHant
Study: 23401618
Drug: E2 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 administration
Study: 15955900
Drug: Lapatinib (GW572016)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (GW572016) administered once daily at doses ranging from 500 to 1,600 mg
Study: 11449341
Drug: Enoxaparin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 40 mg once daily for 6 to 14 days
Study: 9249964
Drug: Functional use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional use of 'blue' and 'yellow' groups assigned on the basis of a biological attribute
Study: 7951125
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally twice a day plus antifungal prophylaxis (fluconazole 50 mg once daily plus amphotericin B 200 mg four times a day) and streptococcal prophylaxis for 10 days after BMT
Study: 31402293
Drug: 50,000 units
Normalized name: Kovia 6.5, 650,000 units/g-10% topical ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 units VitD3 capsules every week for 7 weeks
Study: 31402293
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 300,000 units VitD3 ampoule
Study: 31402293
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of half of the injection dose followed by oral capsule for 4 weeks
Study: 28597922
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg DFN-02
Study: 28597922
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg DFN-02
Study: 28597922
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg DFN-02
Study: 28597922
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg subcutaneous sumatriptan injection
Study: 25204557
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral lenvatinib (5 mg for severe hepatic impairment)
Study: 22068930
Drug: sports-cADHD (90-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: sports-cADHD (90-min athletic activity, twice a week for 6 weeks)
Study: 21059176
Drug: Dapoxetine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine (both doses)
Study: 10429599
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without reorientation measures)
Study: 6457152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of the alpha-blocker thymoxamine given by inhalation
Study: 22677643
Drug: Topical pranoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%
Study: 20461969
Drug: Montelukast (MK)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (MK) 10 mg/d
Study: 18657569
Drug: School-based drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based drug abuse prevention program (12-hour class-based curriculum)
Study: 15709845
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with clinical management
Study: 7547089
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium (120 mg day-1)
Study: 7547089
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium (single dose)
Study: 2326032
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine with diazepam, meperidine, and nitrous oxide
Study: 27909031
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel from flax seed oil
Study: 24467781
Drug: 8‐week group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8‐week group Cognitive Behavioural Therapy (CBT) treatment
Study: 24467781
Drug: Waitlist (8‐week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist (8‐week clinical monitoring preceding treatment)
Study: 22198452
Drug: Tetrabenazine (TBZ)
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrabenazine (TBZ) 12.5-75 mg/d, titrated according to a fixed, flexible schedule
Study: 20633266
Drug: Capsimax (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsimax (2 mg capsaicinoids in a microencapsulated matrix)
Study: 30699151
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B 1mg/kg for 2 weeks and oral Fluconazole 800mg daily for 10 weeks
Study: 29288137
Drug: Men choosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men choosing treatment
Study: 25801892
Drug: Intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive regimen (IR) of cholecalciferol (300.000 UI at baseline and 50.000 UI/monthly)
Study: 25801892
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (SR) of cholecalciferol (25.000 UI monthly)
Study: 23719555
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum vitamin K1 in antihypertension medication users
Study: 16600506
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (0.14 mg/kg)
Study: 10808170
Drug: MF DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MF DPI 50 microg twice daily
Study: 10808170
Drug: MF DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MF DPI 100 microg twice daily
Study: 9228350
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol for 6 weeks, increased in stepwise fashion at 2-week intervals
Study: 8497871
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg/day) with reduced cyclosporine doses
Study: 8497871
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of cyclosporine
Study: 8497871
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of cyclosporine with ketoconazole
Study: 3027838
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg itraconazole twice a day for five days
Study: 3027838
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg itraconazole once a day for five days
Study: 23907764
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral cortisol
Study: 23907764
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin and cortisol
Study: 22272611
Drug: MK-0249 5-mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0249 5-mg daily for 4 weeks
Study: 20369760
Drug: Group M:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M: 2 ml of 0.5% hyperbaric bupivacaine plus morphine 100 microg plus fentanyl 15 microg, mixed in a syringe
Study: 20369760
Drug: Group S:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S: 2 ml of 0.5% bupivacaine followed by morphine 100 microg plus fentanyl 15 microg through a separate syringe
Study: 18662943
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to a combination of emtricitabine, didanosine and efavirenz for 48 weeks
Study: 15728401
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (n = 26, 1-2 mg/day temocapril or trandolapril)
Study: 15728401
Drug: Calcium-channel blockers
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel blockers (CCB, n = 23, 2.5-5 mg/day amlodipine)
Study: 12499343
Drug: Cholecalciferol 25
Normalized name: cholecalciferol 250 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 25 micro g/d
Study: 12499343
Drug: Cholecalciferol 125
Normalized name: cholecalciferol 125 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 125 micro g/d
Study: 12499343
Drug: Cholecalciferol 250
Normalized name: cholecalciferol 250 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 250 micro g/d
Study: 12499343
Drug: Cholecalciferol 0
Normalized name: cholecalciferol 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 0 micro g/d (control)
Study: 12499343
Drug: Total input
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total input from all sources (supplement, food, tissue stores)